State Street’s bioAffinity Technologies BIAF Stock Holding History

State Street’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6K	Buy	1,606 +647	+67%	+$19.8K	﹤0.01%	4132
2026 Q1	$55.1K	Buy	+959	New	+$23.2K	﹤0.01%	4116
2025 Q3	–	Sell	-39	Closed	-$5.05K	–	4293
2025 Q2	$5.05K	Hold	39	–	–	﹤0.01%	4253
2025 Q1	$4.58K	Hold	39	–	–	﹤0.01%	4271
2024 Q4	$16.4K	Hold	39	–	–	﹤0.01%	4249
2024 Q3	$36.6K	Hold	39	–	–	﹤0.01%	4146
2024 Q2	$38K	Hold	39	–	–	﹤0.01%	4192
2024 Q1	$35.6K	Hold	39	–	–	﹤0.01%	4212
2023 Q4	$26.2K	Hold	39	–	–	﹤0.01%	4313
2023 Q3	$21.5K	Hold	39	–	–	﹤0.01%	4434
2023 Q2	$32.2K	Hold	39	–	–	﹤0.01%	4524
2023 Q1	$33.3K	Buy	+39	New	+$33.9K	﹤0.01%	4605

Other funds holding BIAF

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street's BIAF Position: Q2 2026 in Review

State Street increased its bioAffinity Technologies (BIAF) stake by 67% in Q2 2026, buying an estimated $19.8K and bringing the position to 1,606 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4132.

State Street first reported a position in BIAF in Q1 2023 and has held it in 12 quarters since. The position peaked at $55.1K in Q1 2026. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

State Street held 1,606 shares of bioAffinity Technologies worth $19.6K as of Q2 2026.
State Street bought 647 bioAffinity Technologies shares in Q2 2026, an estimated $19.8K.
bioAffinity Technologies made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4132 holding.
State Street first reported a position in bioAffinity Technologies in Q1 2023 and has held it in 12 quarters since.
State Street's bioAffinity Technologies position peaked at $55.1K in Q1 2026.
19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.